In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy

Cancer Research

Volumn 59, Issue 1, 1999, Pages 122-127

  Adams, Earle R ^a   Leffert, Janine J ^a   Craig, Daniel J ^a   Spector, Thomas ^b,c   Pizzorno, Giuseppe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CANCER; DRUG ACCUMULATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; TISSUE LEVEL;

ANIMALS; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME INHIBITORS; FLUOROURACIL; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OXIDOREDUCTASES; URACIL;

EID: 0032896143     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pizzorno, G., Cheng, Y. C., and Handschumacher, R. E. Pyrimidine and purine antimetabolites. In: J. F. Holland, E. Frei, R. C. Bast, D. L. Merten, D. W. Kufe, and R. R. Weichselbaum (eds.), Cancer Medicine, Ed. 4, pp. 923-948. Baltimore: Wiliams & Wilkins, 1996.
2. Martin, D. S. Biochemical modulation. Perspectives and objectives. In: K. R. Harrap and T. A. Connors (eds.) New Avenues in Developmental Cancer Chemotherapy, pp. 113-162. New York: Academic Press, 1987.
3. Peters, G. J., and van Groeningen, C. J. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol., 2: 469-480, 1991.
4. Piedbois, P., Buyse, M., Rustum, Y., Machover, D., Erlichman, C., Carlson, R. W., Valone, F., Labianca, R., Doroshow, J. H., and Petrelli, N. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
5. Spector, T., Cao, S., Rustum, Y. M., Harrington, J. A., and Porter, D. J. T. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil. Cancer Res., 55: 1239-1241, 1995.
6. Okeda, R., Karakama, T., Kimura, S., Toizumi, S., Mitsushima, T., and Yokoyama, Y. Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol., 63: 334-343, 1984.
7. Okeda, R., Shibutani, M., Matsuo, T., Kuroiwa, R., Shimokawa, R., and Tajima, T. Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites monofluoroacetic acid and α-fluoro-β-alanine. Acta Neuropathol., 81: 66-73, 1990.
8. Davis, S. T., Joyner, S. S., Baccanari, D. P., and Spector, T. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem. Pharmacol., 48: 233-236, 1994.
9. Heggie, D., Sommadossi, J-P., Cross, D. S., Huster, W. J., and Diasio, R. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res., 47: 2203-2206, 1987.
10. Shiotani, T., and Weber, G. Purification and properties of dihydropyrimidine dehydrogenase from rat liver. J. Biol. Chem., 256: 219-224, 1981.
11. Naguib, F. N. M., elKouni, M. H., and Cha, S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res., 45: 5402-5412, 1985.
12. Beck, A., Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Renee, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to 5-fluorouracil. Eur. J. Cancer, 30: 1517-1522, 1994.
13. Lu, Z., Zhang, R., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res., 53: 5433-5438, 1993.
14. Porter, D. J. T., Chestnut, W. G., Merrill, B. M., and Spector, T. Mechanism based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J. Biol. Chem., 267: 5236-5242, 1992.
15. Baccanari, D. P., Davis, S. T., Knick, V. C., and Specter, T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc. Natl. Acad. Sci. USA, 90: 11064-11068, 1993.
16. Cao, S., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507-1510, 1994.
17. Baker, S. D., Khor, S. P., Adjei, A. A., Doucette, M., Spector, T., Donehower, R. C., Grochow, L. B., Sartorius, S. E., Noe, D. A., Hohneker, J. A., and Rowinsky, E. K. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol., 14: 3085-3096, 1996.
18. Spector, T., Harrington, J. A., and Porter, D. J. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem. Pharmacol., 46: 2243-2248, 1993.
19. 19F-NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine. Magn. Res. Med., 38: 907-916, 1997.
20. 19F NMR spectroscopy. Magn. Reson. Med., 19: 113-123, 1991.
21. Christophidis, N., Mihaly, G., Vadja, M., and Louis, W. Comparison of liquid-and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin. Chem., 25: 83-87, 1979.
22. Khor, S. P., Lucas, S., Hsieh, A. Y., Schilsky, R., Burris, H., Von Hoff, D. D., and Spector, T. 776C85: effect on renal elimination of 5-fluorouracil and uracil in cancer patients. Proc. Am. Assoc. Cancer Res., 37: 371, 1996.
23. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol., 8: 1868-1873, 1990.
24. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA. 87: 492-496, 1990.
25. Arellano, M., Malet-Martino, M., Martino, R., and Spector, T. 5-Ethynyluracil (EU): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. Br. J. Cancer, 76: 1170-1180, 1997.
26. Davis, S. T., Baccanari, D. P., and Spector, T. 5-Ethynyluracil (5-EU, 776C85): effects on thymidylate synthase (TS) inhibition and incorporation of 5-FU into RNA in mice bearing MOPC-315 tumors. Proc. Am. Assoc. Cancer Res., 36: 292, 1995.
27. Cao, S., Baccanari, D. P., Joyner, S. S., Davis, S. T., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res., 55: 6227-6230, 1995.
28. Zhang, R., Soong, S-J., Liu, T., Barnes, S., and Diasio, R. B. Pharmacokinetics and tissue distribution of 2-fluoro-β-alanine in rats potential relevance to toxicity pattern of 5-fluorouracil. Drug Metab. Dispos., 20: 113-119, 1992.
29. Moertel, C. G., Reitemeier, R. J., Bolton, C. F., and Shorter, R. G. Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother. Rep., 41: 15-18, 1964.
30. Riehl, J. B., and Brown, W. J. Acute cerebellar syndrome secondary to 5-FU therapy. Neurology, 14: 961-967, 1964.
31. Yeh, K. H., and Cheng, A. L. High-dose 5-fluorouracil infusional therapy is associated with hyperammoneamia, lactic acidosis and encephalopathy. Br. J. Cancer, 75: 464-465, 1997.
32. Liu, M-P., Beigelman, L., Levy, E., Handschumacher, E. R., and Pizzorno, G. The discrete roles of hepatocytes and nonparenchymal cells in uridine catabolism as a component of its homeostasis. Am. J. Physiol., 274: G1018-G1023, 1998.